Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE 1
2023-507415-35-00Phase 3Completed
- Sponsor
- Sun Pharma
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in psoriatic arthritis (PsA) and plaque psoriasis (2 arms), sponsored by Sun Pharma. Primary endpoint: ACR20 response at Week 24. Started May 2024; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on 2023-507415-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507415-35-00.